{"id":1012802,"date":"2026-10-22T16:05:29","date_gmt":"2026-10-22T20:05:29","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/"},"modified":"2026-10-22T16:05:29","modified_gmt":"2026-10-22T20:05:29","slug":"kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/","title":{"rendered":"Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026"},"content":{"rendered":"
\n

WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc.<\/a> (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2026 financial results on October 29, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. <\/p>\n

To join the video call or view the livestreamed webcast, please register via this link<\/strong><\/a>, or visit \u201cNews and Events<\/a>\u201d in the Investors section of the Company\u2019s website at www.kymeratx.com<\/a>. A replay of the webcast will be archived and available following the event.<\/p>\n

\n About Kymera Therapeutics<\/strong>\u00a0
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients\u2019 lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston\u2019s top workplaces for the past several years. For more information about our science, pipeline and people, please visit\u00a0www.kymeratx.com<\/a>\u00a0or follow us on\u00a0X<\/a>\u00a0or\u00a0LinkedIn<\/a>.<\/p>\n

\n Investor Contact:<\/strong>\u00a0
Justine Koenigsberg
investors@kymeratx.com<\/a>
857-285-5300\u00a0<\/p>\n

\n Media Contact: <\/strong>
\n
Matthew Henson
media@kymeratx.com<\/a>
857-285-5300<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2026 financial results on October 29, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit \u201cNews and Events\u201d in the Investors section of the Company\u2019s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera Therapeutics\u00a0Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that … <\/p>\n

Continue reading “Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1012802","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nKymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2026 financial results on October 29, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit \u201cNews and Events\u201d in the Investors section of the Company\u2019s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera Therapeutics\u00a0Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that … Continue reading "Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-22T20:05:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDg0MyM3OTA5ODY0IzIyMDA4MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026\",\"datePublished\":\"2026-10-22T20:05:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/\"},\"wordCount\":252,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDg0MyM3OTA5ODY0IzIyMDA4MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/\",\"name\":\"Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDg0MyM3OTA5ODY0IzIyMDA4MzI=\",\"datePublished\":\"2026-10-22T20:05:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDg0MyM3OTA5ODY0IzIyMDA4MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDg0MyM3OTA5ODY0IzIyMDA4MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/","og_locale":"en_US","og_type":"article","og_title":"Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 - Market Newsdesk","og_description":"WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2026 financial results on October 29, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit \u201cNews and Events\u201d in the Investors section of the Company\u2019s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera Therapeutics\u00a0Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that … Continue reading \"Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-22T20:05:29+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDg0MyM3OTA5ODY0IzIyMDA4MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026","datePublished":"2026-10-22T20:05:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/"},"wordCount":252,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDg0MyM3OTA5ODY0IzIyMDA4MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/","name":"Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDg0MyM3OTA5ODY0IzIyMDA4MzI=","datePublished":"2026-10-22T20:05:29+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDg0MyM3OTA5ODY0IzIyMDA4MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDg0MyM3OTA5ODY0IzIyMDA4MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/kymera-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1012802"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012802\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1012802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1012802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1012802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}